Active surveillance for low-risk prostate cancer: some questions are answered, but many questions remain.

[1]  M. Roobol,et al.  Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. , 2013, European urology.

[2]  J. Pow-Sang,et al.  Enrollment criteria controversies for active surveillance and triggers for conversion to treatment in prostate cancer. , 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

[3]  M. Roobol,et al.  Radical prostatectomy for low-risk prostate cancer following initial active surveillance: results from a prospective observational study. , 2012, European urology.

[4]  R. V. D. van den Bergh,et al.  Predictors of unfavourable repeat biopsy results in men participating in a prospective active surveillance program. , 2012, European urology.

[5]  Chris Metcalfe,et al.  Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study , 2012, BMJ : British Medical Journal.

[6]  M. Regan,et al.  Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance. , 2011, The Journal of urology.

[7]  W. Kassouf,et al.  Relationship between initial PSA density with future PSA kinetics and repeat biopsies in men with prostate cancer on active surveillance , 2010, Prostate Cancer and Prostatic Diseases.

[8]  B. Guillonneau,et al.  Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance. , 2008, The Journal of urology.

[9]  Alexandre Mamedov,et al.  Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.